Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction.
Paul D Geenty, Ann T Gregory, Mark Nolan, A Robert Denniss, Salvatore Pepe, Aaron L Sverdlov, Liza Thomas
Author Information
- Paul D Geenty: Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia.
- Ann T Gregory: Heart, Lung and Circulation, Sydney, NSW, Australia.
- Mark Nolan: Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
- A Robert Denniss: Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Heart, Lung and Circulation, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Blacktown Hospital, and Western Sydney University, Sydney, NSW, Australia.
- Salvatore Pepe: Heart, Lung and Circulation, Sydney, NSW, Australia; Heart Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne; Department of Paediatrics, The University of Melbourne, Melbourne, Vic, Australia.
- Aaron L Sverdlov: Newcastle Centre of Excellence in Cardio-Oncology, The University of Newcastle; Hunter Medical Research Institute; Calvary Mater Newcastle, Hunter New England Health, Newcastle, NSW, Australia; Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia. Electronic address: aaron.sverdlov@newcastle.edu.au.
- Liza Thomas: Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia; Southwest Clinical School, University of New South Wales, NSW, Australia. Electronic address: liza.thomas@sydney.edu.au.
No abstract text available.
Humans
Anthracyclines
Stroke Volume
Neoplasms
Antineoplastic Agents
Cardiotoxicity
Medical Oncology
Cardiovascular Diseases
Cardio-Oncology
Anthracyclines
Antineoplastic Agents
